Hasan Mervan Aytac, Yasemin Oyaci, Eren Aytac, Mustafa Pehlivan, Furkan Bahadir Alptekin, Sacide Pehlivan
{"title":"Evaluation of leptin and leptin receptor gene polymorphisms in bipolar disorder: focus on depressive episodes with atypical features.","authors":"Hasan Mervan Aytac, Yasemin Oyaci, Eren Aytac, Mustafa Pehlivan, Furkan Bahadir Alptekin, Sacide Pehlivan","doi":"10.1080/13813455.2025.2507751","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective</b>: Our study aims to examine the effect of leptin (<i>LEP</i>) (-2548 G > A) (rs7799039) and leptin receptor (<i>LEPR</i>) (668 A > G) (rs1137101) gene polymorphisms on the etiopathogenesis of bipolar disorder (BD) by comparing them with a control group, as well as their association with depressive episodes featuring atypical symptoms.</p><p><p><b>Methods</b>: The study included a sample of 103 individuals with BD and 103 healthy volunteers. Gene polymorphisms were identified from DNA samples through polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).</p><p><p><b>Results</b>: The distribution of <i>LEPR</i> genotypes was significantly different between BD patients and healthy controls. Specifically, the homozygous <i>LEPR</i> GG genotype was more common in the control group than in BD patients. Additionally, genotype frequency distributions among BD patients varied significantly based on the presence of atypical depressive episodes. The <i>LEPR</i> AA and <i>LEP</i> GG genotypes were significantly more common among patients with a history of atypical depression. Logistic regression showed that the <i>LEP</i> polymorphism and Hamilton Depression Rating Scale (HAM-D) score predict atypical depression in BD.</p><p><p><b>Conclusion</b>: In summary, while the <i>LEPR</i> polymorphism is linked to BD, the <i>LEP</i> polymorphism and symptom severity appear to predict atypical depressive episodes.</p>","PeriodicalId":8331,"journal":{"name":"Archives of Physiology and Biochemistry","volume":" ","pages":"1-9"},"PeriodicalIF":2.7000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Physiology and Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13813455.2025.2507751","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Our study aims to examine the effect of leptin (LEP) (-2548 G > A) (rs7799039) and leptin receptor (LEPR) (668 A > G) (rs1137101) gene polymorphisms on the etiopathogenesis of bipolar disorder (BD) by comparing them with a control group, as well as their association with depressive episodes featuring atypical symptoms.
Methods: The study included a sample of 103 individuals with BD and 103 healthy volunteers. Gene polymorphisms were identified from DNA samples through polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
Results: The distribution of LEPR genotypes was significantly different between BD patients and healthy controls. Specifically, the homozygous LEPR GG genotype was more common in the control group than in BD patients. Additionally, genotype frequency distributions among BD patients varied significantly based on the presence of atypical depressive episodes. The LEPR AA and LEP GG genotypes were significantly more common among patients with a history of atypical depression. Logistic regression showed that the LEP polymorphism and Hamilton Depression Rating Scale (HAM-D) score predict atypical depression in BD.
Conclusion: In summary, while the LEPR polymorphism is linked to BD, the LEP polymorphism and symptom severity appear to predict atypical depressive episodes.
期刊介绍:
Archives of Physiology and Biochemistry: The Journal of Metabolic Diseases is an international peer-reviewed journal which has been relaunched to meet the increasing demand for integrated publication on molecular, biochemical and cellular aspects of metabolic diseases, as well as clinical and therapeutic strategies for their treatment. It publishes full-length original articles, rapid papers, reviews and mini-reviews on selected topics. It is the overall goal of the journal to disseminate novel approaches to an improved understanding of major metabolic disorders.
The scope encompasses all topics related to the molecular and cellular pathophysiology of metabolic diseases like obesity, type 2 diabetes and the metabolic syndrome, and their associated complications.
Clinical studies are considered as an integral part of the Journal and should be related to one of the following topics:
-Dysregulation of hormone receptors and signal transduction
-Contribution of gene variants and gene regulatory processes
-Impairment of intermediary metabolism at the cellular level
-Secretion and metabolism of peptides and other factors that mediate cellular crosstalk
-Therapeutic strategies for managing metabolic diseases
Special issues dedicated to topics in the field will be published regularly.